SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gene therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SnowShredder who wrote (291)6/9/2004 2:03:08 PM
From: Mike McFarland  Read Replies (1) of 319
 
Got a question for ya--does anybody know if you
can change a clinical trial or do companies have
to do a whole new protocol and go right back to
square one?

The reason I ask, is that a fellow on Yahoo/Tgen,
'nerdseeksblond' has several times brought up
one of the asgt abstracts {[760] Dual Therapeutic
Utility of Proteasome Modulating Agents for Pharmico-
Gene Therapy of the Cystic Fibrosis Airway}.

I'm not sure this does anything for Targeted Genetics,
because I assume that they would have to go back
and do a phase I trial.

I guess at least one of the drugs they experimented
with is a chemo drug, doxorubicin. The paper to read,
as far as I can tell, is J Virol. 2004 Mar;78(6):2863-74.

Actually, here is his original post. Which I
suppose is a very good question. <redfaced...> I
hate to admit it went in one ear and out the other
when I first read it.

messages.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News